Darunavir
Darunavir
CLINICAL USE
Protease inhibitor:Treatment of HIV infection with 100 mg of ritonavir, in combination with other antiretroviral medication
DOSE IN NORMAL RENAL FUNCTION
600 mg twice daily
PHARMACOKINETICS
Molecular weight                           :593.7 (as ethanolate) %Protein binding                           :95 %Excreted unchanged in urine     : 7.7 Volume of distribution (L/kg)       :29.1–147.1 litres (81.1–180.9 litres with ritonavir)half-life – normal/ESRD (hrs)      :15 (with ritonavir)/Unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function HD                     :Unlikely to be dialysed. Dose as in normal renal functionHDF/high flux   :Unlikely to be dialysed. Dose as in normal renal functionCAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAntibacterials: rifabutin concentration increased – reduce dose of rifabutin; darunavir concentration reduced by rifampicin – avoid concomitant useAntidepressants: possibly reduced concentration of paroxetine and sertraline; darunavir concentration reduced by St John’s wort – avoid concomitant use ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home